Thorough QT (TQT) clinical trial evaluating the effects of deutetrabenazine (SD 809) on cardiac repolarisation in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 23 Jun 2016
At a glance
- Drugs Deutetrabenazine (Primary) ; Moxifloxacin; Tetrabenazine
- Indications Chorea
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Auspex Pharmaceuticals
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology
- 20 Jan 2015 New trial record
- 12 Jan 2015 Results published in an Auspex Pharmaceuticals media release.